lorazepam has been researched along with Neoplasms in 29 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer." | 9.24 | Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 9.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 9.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 7.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "The current study was a secondary analysis of a randomized controlled trial to compare the effect of lorazepam versus placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium." | 5.27 | The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. ( Arthur, J; Bruera, E; Dalal, S; Dev, R; Dibaj, SS; Hess, K; Hui, D; Reddy, S, 2018) |
| "To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer." | 5.24 | Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017) |
| "The topical gel known as "ABH gel," comprising lorazepam (Ativan(®)), diphenhydramine (Benadryl(®)), and haloperidol (Haldol(®)), is frequently used to treat nausea because of its perceived efficacy, relatively low cost, and ease of use in the home setting." | 5.19 | A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea. ( Coyne, PJ; Dodson, PW; Fletcher, DS; Parker, GG; Smith, TJ; Wan, W, 2014) |
| "To compare the effectiveness and side effects of antiemetic regimens using ondansetron alone (O) versus ondansetron plus dexamethasone (OD) versus ondansetron plus dexamethasone plus lorazepam (ODA) in the prevention of emesis induced by cisplatin-based chemotherapy." | 5.07 | A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. ( Ahn, MJ; Choi, SS; Kim, SH; Lee, JS; Lee, KH; Suh, C, 1994) |
| "The efficacy and tolerability of tropisetron in preventing cisplatin-induced nausea and vomiting was studied in 2 open trials and compared with the efficacy and tolerability of metoclopramide plus lorazepam in a randomised crossover trial." | 5.07 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients. ( Antonacci, RA; Berruti, A; Dogliotti, L; Faggiuolo, R; Ortega, C; Pazè, E, 1992) |
| "Lorazepam was compared to placebo to assess its control of nausea and vomiting in patients receiving cytotoxic chemotherapy and prochlorperazine." | 5.05 | Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine. ( Bingham, J; Bishop, JF; Cooper, IA; Hillcoat, BL; Long, M; Matthews, JP; Olver, IN; Wolf, MM, 1984) |
| " In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome." | 4.80 | Human UDP-glucuronosyltransferases: metabolism, expression, and disease. ( Strassburg, CP; Tukey, RH, 2000) |
| " Delayed emesis following Cycle 1 of carboplatin was observed in 30% of patients." | 3.83 | Delayed nausea and vomiting from carboplatin doublet chemotherapy. ( Baggstrom, MQ; Chitneni, P; Gao, F; Govindan, R; Mann, J; Morgensztern, D; Waqar, MA; Waqar, SN; Williams, K, 2016) |
| "To examine whether hepatic drug metabolism is altered in patients with cystic fibrosis (CF), we evaluated the pharmacokinetics of three model pharmacologic substrates (antipyrine, a marker of hepatic oxidative metabolism; lorazepam, a marker of hepatic glucuronosyltransferase activity; and indocyanine green (ICG), a marker of hepatic blood flow and biliary secretion) in 14 patients with CF (14." | 3.68 | Enhanced hepatic drug clearance in patients with cystic fibrosis. ( Crom, WR; Evans, WE; Kearns, GL; Mallory, GB, 1990) |
| "More than 2,000 medically ill patients with delirium have been treated by intravenous administration of a combination of haloperidol and lorazepam." | 3.67 | Emergency intravenous sedation of the delirious, medically ill patient. ( Adams, F, 1988) |
| "A clinical study was carried out in 73 neoplastic patients suffering from anxiety and other emotional upsets to assess the effectiveness and tolerance of lorazepam." | 3.65 | Anxiety therapy in the neoplastic patient. ( Battelli, T; Bonsignori, M; Manocchi, P; Rossi, G, 1976) |
| "Delirium is the second most common psychiatric diagnosis among hospitalized elderly cancer patients." | 2.38 | Delirium in cancer patients. ( Holland, J; Stiefel, F, 1991) |
| "Lorazepam was given most often because of anxiety and agitation, oxazepam to induce sleep and midazolam in five cases of terminal sedation." | 1.35 | [Indications and use of benzodiazepines in a palliative care unit]. ( Elsner, F; Krumm, N; Radbruch, L; Schroers, O; Stiel, S, 2008) |
| "Midazolam was used in 18 PS cases (10%)." | 1.35 | Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center. ( Boohene, J; Bruera, E; Calderon, B; Curry Iii, E; Elsayem, A; Hung, F; Munsell, MF, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (41.38) | 18.7374 |
| 1990's | 8 (27.59) | 18.2507 |
| 2000's | 4 (13.79) | 29.6817 |
| 2010's | 5 (17.24) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tukey, RH | 1 |
| Strassburg, CP | 1 |
| Hui, D | 2 |
| Frisbee-Hume, S | 1 |
| Wilson, A | 1 |
| Dibaj, SS | 2 |
| Nguyen, T | 1 |
| De La Cruz, M | 1 |
| Walker, P | 1 |
| Zhukovsky, DS | 1 |
| Delgado-Guay, M | 1 |
| Vidal, M | 1 |
| Epner, D | 1 |
| Reddy, A | 1 |
| Tanco, K | 1 |
| Williams, J | 1 |
| Hall, S | 1 |
| Liu, D | 1 |
| Hess, K | 2 |
| Amin, S | 1 |
| Breitbart, W | 1 |
| Bruera, E | 3 |
| Arthur, J | 1 |
| Dev, R | 1 |
| Dalal, S | 1 |
| Reddy, S | 1 |
| Shrikant Kulkarni, N | 1 |
| Fletcher, DS | 1 |
| Coyne, PJ | 1 |
| Dodson, PW | 1 |
| Parker, GG | 1 |
| Wan, W | 1 |
| Smith, TJ | 1 |
| Waqar, SN | 1 |
| Mann, J | 1 |
| Baggstrom, MQ | 1 |
| Waqar, MA | 1 |
| Chitneni, P | 1 |
| Williams, K | 1 |
| Gao, F | 1 |
| Morgensztern, D | 1 |
| Govindan, R | 1 |
| Stiel, S | 1 |
| Krumm, N | 1 |
| Schroers, O | 1 |
| Radbruch, L | 1 |
| Elsner, F | 1 |
| Bleicher, J | 1 |
| Bhaskara, A | 1 |
| Huyck, T | 1 |
| Constantino, S | 1 |
| Bardia, A | 1 |
| Loprinzi, CL | 1 |
| Silberstein, PT | 1 |
| Elsayem, A | 1 |
| Curry Iii, E | 1 |
| Boohene, J | 1 |
| Munsell, MF | 1 |
| Calderon, B | 1 |
| Hung, F | 1 |
| Maher, J | 1 |
| Mizuguchi, T | 1 |
| Tanaka, T | 1 |
| Higuchi, S | 1 |
| Bishop, JF | 2 |
| Olver, IN | 1 |
| Wolf, MM | 2 |
| Matthews, JP | 2 |
| Long, M | 1 |
| Bingham, J | 1 |
| Hillcoat, BL | 1 |
| Cooper, IA | 1 |
| Gagen, M | 1 |
| Gochnour, D | 1 |
| Young, D | 1 |
| Gaginella, T | 1 |
| Neidhart, J | 1 |
| Warde, P | 1 |
| Cantwell, B | 1 |
| Fennelly, J | 1 |
| Powderly, W | 1 |
| Conroy, R | 1 |
| Ahn, MJ | 1 |
| Lee, JS | 1 |
| Lee, KH | 1 |
| Suh, C | 1 |
| Choi, SS | 1 |
| Kim, SH | 1 |
| Clerico, M | 1 |
| Bertetto, O | 1 |
| Morandini, MP | 1 |
| Cardinali, C | 1 |
| Giaccone, G | 1 |
| Battelli, T | 1 |
| Bonsignori, M | 1 |
| Manocchi, P | 1 |
| Rossi, G | 1 |
| Dogliotti, L | 1 |
| Antonacci, RA | 1 |
| Pazè, E | 1 |
| Ortega, C | 1 |
| Berruti, A | 1 |
| Faggiuolo, R | 1 |
| Oliver, IN | 1 |
| Reynolds, S | 1 |
| Walpole, E | 1 |
| Rischin, D | 1 |
| Buchanan, L | 1 |
| Tan, LG | 1 |
| Stiefel, F | 1 |
| Holland, J | 1 |
| González Barón, M | 1 |
| Chacón, JI | 1 |
| García Girón, C | 1 |
| Ordóñez Gallego, A | 1 |
| García de Paredes, ML | 1 |
| Feliu, J | 1 |
| Zamora, P | 1 |
| Herranz, C | 1 |
| Garrido, P | 1 |
| Artal, A | 1 |
| Roila, F | 1 |
| Basurto, C | 1 |
| Bracarda, S | 1 |
| Picciafuoco, M | 1 |
| Ballatori, E | 1 |
| Del Favero, A | 1 |
| Tonato, M | 1 |
| Kearns, GL | 1 |
| Mallory, GB | 1 |
| Crom, WR | 1 |
| Evans, WE | 1 |
| Adams, F | 2 |
| Kearsley, JH | 1 |
| Williams, AM | 1 |
| Fiumara, AM | 1 |
| Furste, AB | 1 |
| Davis, MP | 1 |
| Gutterman, L | 1 |
| Pritchard, JD | 1 |
| Wheeler, W | 1 |
| Enck, RE | 1 |
| Fernandez, F | 1 |
| Andersson, BS | 1 |
| Laszlo, J | 1 |
| Clark, RA | 1 |
| Hanson, DC | 1 |
| Tyson, L | 1 |
| Crumpler, L | 1 |
| Gralla, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit[NCT01949662] | Phase 2 | 93 participants (Actual) | Interventional | 2014-01-31 | Active, not recruiting | ||
| HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial[NCT04833023] | Phase 3 | 72 participants (Anticipated) | Interventional | 2022-05-18 | Recruiting | ||
| Open-label Randomized Controlled Trial of Oral Transmucosal Haloperidol and Olanzapine in the Treatment of Terminal Delirium[NCT04750395] | Phase 2 | 80 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Absolute score of Richmond Agitation-Sedation Scale at 8 hr, points. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: 8 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | -2.5 |
| Control Group (Placebo & Haloperidol) | -0.7 |
The primary outcome was change in Richmond Agitation-Sedation Scale score from baseline to 8 hours after treatment administration. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | -4.1 |
| Control Group (Placebo & Haloperidol) | -2.3 |
Change in Richmond Agitation-Sedation Scale score from baseline to 30 min. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 30 minutes
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | -3.6 |
| Control Group (Placebo & Haloperidol) | -1.6 |
Number of participants with Richmond Agitation-Sedation Scale score >=1 within 8 hr. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | 8 |
| Control Group (Placebo & Haloperidol) | 22 |
2 reviews available for lorazepam and Neoplasms
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; | 2000 |
Delirium in cancer patients.
Topics: Aged; Delirium; Diagnosis, Differential; Haloperidol; Humans; Lorazepam; Neoplasms; Neuropsychologic | 1991 |
13 trials available for lorazepam and Neoplasms
| Article | Year |
|---|---|
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium.
Topics: Adult; Aged; Aged, 80 and over; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; Lo | 2018 |
Lorazepam Added to Haloperidol Effective for Agitated Delirium in End-of-Life Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Drug Therapy, Combination; Female; H | 2018 |
A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiemetics; Cross-Over Studies; Diphenhydramine; | 2014 |
Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1984 |
A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy-induced vomiting.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; D | 1984 |
A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Topics: Adult; Aged; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1994 |
Antiemetic activity of oral lorazepam in addition to methylprednisolone and metoclopramide in the prophylactic treatment of vomiting induced by cisplatin. A double-blind, placebo-controlled study with crossover design.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lorazepam; M | 1993 |
Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients.
Topics: Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Indoles; Lorazepam; Male; Metoclopramide; Middl | 1992 |
A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy.
Topics: Adult; Aged; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; | 1992 |
Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam.
Topics: Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Methyl | 1991 |
Antiemetic superiority of lorazepam over oxazepam and methylprednisolone as premedicants for patients receiving cisplatin-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Cisplatin; Female; Humans; Lorazepam; Male; Methylprednisolone | 1989 |
A pilot study comparing decadron (D)/ativan (A) versus reglan (R)/decadron (D)/benadryl (B) as antiemetic regimens.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1988 |
14 other studies available for lorazepam and Neoplasms
| Article | Year |
|---|---|
Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lora | 2016 |
[Indications and use of benzodiazepines in a palliative care unit].
Topics: Adult; Aged; Aged, 80 and over; Benzodiazepines; Female; Humans; Lorazepam; Male; Middle Aged; Neopl | 2008 |
Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clini | 2008 |
Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center.
Topics: Adult; Aged; Aged, 80 and over; Cancer Care Facilities; Chlorpromazine; Female; Humans; Hypnotics an | 2009 |
Intravenous lorazepam to prevent nausea and vomiting associated with cancer chemotherapy.
Topics: Anti-Anxiety Agents; Antineoplastic Agents; Humans; Injections, Intravenous; Lorazepam; Nausea; Neop | 1981 |
[Preoperative anxiety and effect of lorazepam (author's transl)].
Topics: Adult; Anti-Anxiety Agents; Anxiety; Female; Flicker Fusion; Humans; Lorazepam; Male; Middle Aged; N | 1982 |
Alleviation of chemotherapy induced emesis by oral lorazepam and domperidone.
Topics: Adult; Antineoplastic Agents; Domperidone; Drug Therapy, Combination; Female; Humans; Lorazepam; Mal | 1983 |
Anxiety therapy in the neoplastic patient.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Female; Humans; Lorazepam; Male; Middl | 1976 |
A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Diphenhydramine; Drug Eval | 1990 |
Enhanced hepatic drug clearance in patients with cystic fibrosis.
Topics: Adolescent; Adult; Antipyrine; Biotransformation; Cystic Fibrosis; Female; Humans; Indocyanine Green | 1990 |
Emergency intravenous sedation of the delirious, medically ill patient.
Topics: Critical Care; Delirium; Drug Therapy, Combination; Haloperidol; Humans; Hydromorphone; Infusions, I | 1988 |
Corticosteroids and lorazepam as antiemetics in cancer chemotherapy.
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Lora | 1986 |
Emergency pharmacotherapy of delirium in the critically ill cancer patient.
Topics: Adult; Aged; Delirium; Drug Therapy, Combination; Emergencies; Female; Haloperidol; Humans; Infusion | 1986 |
Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic, and anxiolytic effects.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Cisplatin; Female; Huma | 1985 |